Could 2 HPV vaccine doses be enough? new study says maybe.

NCT ID NCT03943875

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether 2 doses of the HPV vaccine (Gardasil 9) protect as well as the standard 3 doses in people aged 15 to 26. Researchers measured antibody levels against nine HPV types. The goal is to see if a simpler schedule could work, making vaccination easier and cheaper.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

9-valent HPV vaccine (Gardasil 9)

What this could lead to

If 2 doses work as well as 3, it could simplify HPV vaccination schedules, reduce costs, and make it easier for more people to get protected against HPV-related cancers.

What could go wrong

This is a completed Phase 4 study, but it only measured short-term antibody responses, not long-term cancer prevention. Two doses may not provide the same lasting protection as three doses.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMA VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Texas Medical Branch

    Galveston, Texas, 77555, United States